Skip to content

Advertisement

  • Research
  • Open Access

Analysis of the causes of failure after radical surgery in patients with PT3N0M0 thoracic esophageal squamous cell carcinoma and consideration of postoperative radiotherapy

  • 1,
  • 2,
  • 1Email author,
  • 1,
  • 1 and
  • 1
World Journal of Surgical Oncology201715:192

https://doi.org/10.1186/s12957-017-1259-4

  • Received: 13 July 2017
  • Accepted: 15 October 2017
  • Published:

Abstract

Background

Five-year overall survival rate of TESCC after surgery is low (approximately 30% to 60%), so it is meaningful to discuss the significance of PORT.

Methods

We retrospectively collected the data of 227 patients with PT3N0M0 esophageal cancer (EC). The failure pattern after surgery was analyzed. Difference of adjuvant PORT in patients with PT3N0M0 TESCC and the appropriate population were explored based on the relevant studies.

Results

There were 58 cases with intrathoracic locoregional recurrence (LRR) after radical surgery and 27 cases with distant metastasis, including 10 cases of recurrence. The recurrence rate of mediastinal lymph nodes in the thoracic cavity was 50.0%. Univariate analysis revealed that compared with patients with middle and lower thoracic EC, the 3/5-year survival rate of patients with upper thoracic EC was significantly lower, accompanied with remarkably higher thoracic LRR. Compared with those with moderately- and well-differentiated TESCC, the 3/5-year survival rate of patients with poorly differentiated TESCC was significantly lower, whereas the distant metastasis rate was notably higher. Multivariate analysis revealed that different lesion locations and different pathologic differentiation were the independent prognostic factors. The lesion location and degree of differentiation were the independent influencing factors for thoracic LRR and distant metastasis, respectively.

Conclusion

The intrathoracic LRR is the major failure pattern for patients with PT3N0M0 TESCC after conventional two-field lymphadenectomy. In addition, recurrence rate of PT3N0M0 TESCC was significantly higher in upper thoracic EC than in middle and lower thoracic EC. PORT is recommended to patients with PT3N0M0 upper TESCC.

Keywords

  • Esophageal cancer
  • Surgical treatment
  • Recurrence
  • Prognosis
  • Postoperative radiotherapy

Background

Esophageal squamous cell carcinoma (ESCC) is a common type of esophageal carcinoma (EC), which is characterized by rapid development and fatal prognosis in most patients. Radical esophagectomy (RO) is the mainstay of treatment for PT3N0M0 thoracic esophageal squamous cell carcinoma (TESCC) [1, 2]. Five-year overall survival (OS) rate after surgery is approximately 30 to 60%, whereas the recurrence rate is as high as 43% after RO [15]. Notably, the recurrence is the major cause of treatment failure in patients with PT3N0M0 TESCC.

In China, it has been reported that adjuvant postoperative radiotherapy (PORT) or PORT combined with postoperative chemotherapy (POCT) contributed to the reduction of postoperative recurrence in clinical practice [1, 6]. Currently, few literatures reported whether adjuvant PORT or combined RCT can reduce recurrence rate of PT3N0M0 TESCC. Yang et al. [7] reported that compared with surgery alone, postoperative assisted three-dimensional conformal radiotherapy (3D-CRT) decreased postoperative recurrence rate of PT3N0M0 TESCC and increased the 5-year disease-free survival (DFS) and OS. Thus, adjuvant PORT was recommended for patients with PT3N0M0 TESCC.

It is of great significance to understand the causes and patterns of treatment failure in postoperative patients with EC to further clarify the recurrent sites of patients and guide their follow-up treatment. To pinpoint the influencing factors of postoperative recurrence of PT3N0M0 TESCC, we investigated the failure pattern of PT3N0M0 TESCC and explored the extent and feasibility of irradiation target after surgery.

Methods

Patients

From January 2007 to December 2010, we collected the data of 227 patients (160 males and 67 females) aged from 43 to 79 with a median age of 62 who received esophagectomy in the Department of Thoracic Surgery, the Fourth Hospital of Hebei Medical University. The number of patients with upper, middle, and lower thoracic EC was 33, 153, and 41, respectively. Surgical procedure consisted of left (n = 212) and right (n = 15) thoracic esophagectomy. The median length of esophageal lesions was 5.0 cm (range 0.8–10.0 cm). The dissected lymph node numbers ranged from 5 to 28, with a median number of 10. Contrast-enhanced chest CT scan showed mediastinal lymph nodes with short axis diameter < 10 mm in 44 patients preoperatively. Intraoperative study found the presence of moderate to severe inflammatory adhesions between the esophagus and peripheral tissues and organs due to esophageal lesions in 97 cases, while mild adhesions or without adhesions in 130 cases. The procedures were approved by the Ethics Committee of the Fourth Hospital of Hebei Medical University. All patients signed informed consent. Needle aspiration biopsy was used for the enlarged lymph nodes in the superficial areas, such as supraclavicular area and neck. The diagnosis of mediastinum intrathoracic and celiac lymph nodes is based on the criteria in previous reports. The diagnosis of anastomotic recurrence is based on electronic gastroscopy and pathological biopsy.

Inclusion and exclusion criteria

Inclusion criteria are as follows: (1) patients who received the total esophagectomy + two-field (complete mediastinal + abdominal) lymph node dissection by means of thoracotomy on both left and right sides in the Department of Thoracic Surgery, the Fourth Hospital of Hebei Medical University; (2) patients undergoing RO; (3) patients with postoperative pathological diagnosis of TESCC; and (4) patients with pathological stage PT3N0M0. Exclusion criteria are as follows: (1) patients with non-squamous cell carcinoma (SCC); (2) patients with no prior adjuvant PORT and/or postoperative chemotherapy (POCT); (3) patients with positive esophageal stump; and (4) patients with perioperative death and lack of follow-up data.

Diagnostic criteria of treatment failure

Location of treatment failure and time were confirmed by reviewing data of patients with regular visits in our hospital, including surgical records and imaging reports (CT, MRI, and ECT), as well as pathological and cytological reports.

Recurrence type

Intrathoracic locoregional failure (LRF) refers to mediastinal lymphatic metastasis, recurrence of the original esophageal neoplasms, and anastomotic recurrence. According to the seventh edition (2009) of the Union for International Cancer Control (UICC) on Cancer TNM staging system, LRF included the supraclavicular lymph node metastasis (SLNM) and abdominal lymph node metastasis (including left gastric and hepatic and splenic hilar lymph nodes as well as those around the celiac artery). Distant metastasis refers to hepatic, pulmonary, osseous, subcutaneous, and pleural metastases as well as metastasis to other parts of the body (such as armpit and inguina).

Diagnostic criteria of postoperative lymphatic metastasis/recurrence

Enlarged superficial lymph nodes were mainly confirmed by cytology examination or postoperative pathology. CT diagnostic criteria of the lymph node in other areas are as follows: (1) short axial diameter of lymph node ≥ 10 mm, as compared with standard axial diameter ≥ 3 mm and ≥ 5 mm in special parts of the body, such as the paraesophageal area and tracheoesophageal groove; (2) small lymph nodes with irregular shape and low density necrosis at the center; (3) clustering of lymph nodes (n ≥ 3); and (4) lack of boundaries between lymph node and peripheral fat due to extracapsular invasion.

Follow-up

The followed-up period of all patients were ended until December 31, 2015. Patients were instructed to return regularly for follow-up every 3–6 months for the first year and 6 to 12 months in the following years. Review items involved neck and abdomen ultrasound and contrast-enhanced chest CT/MR as well as ECT and PET CT examination when necessary. In terms of suspected cervical lymph node enlargement by ultrasound, needle aspiration biopsy or contrast-enhanced CT would be recommended, whereas suspected lymphadenopathy by abdominal ultrasound required contrast-enhanced abdominal CT/MR examination. The number of patients that followed up for 1, 3, and 5 years was 193, 136, and 109, respectively, and a total of 131 patients died at the last follow-up.

Statistical analysis

We used SPSS 19.0 for the data analysis. The comparison of counting data was performed using chi-square test. Kaplan-Meier method was utilized to calculate OS rate, recurrence rate, and distant metastasis rate. Log-rank method and Cox regression model were applied to univariate analysis and multivariate analysis of the prognostic factors, respectively. Test level was α = 0.05.

Results

Analysis of failure pattern in the whole group

In the last follow-up, there were a recurrence of intrathoracic locoregional in 58 patients (LRR; recurrence rate of 25.6% and median recurrence time of 16.4 months, ranging from 2.2 to 81.9 months), distant metastasis in 27 patients (metastasis rate of 11.9% and median time of 24.5 months, ranging from 2.0 to 66.0 months), and recurrence with distant metastases in 10 patients. In 58 patients with recurrence, the number of supraclavicular, intrathoracic, abdominal, and anastomotic lymph node recurrence was 12, 39, 10, and 6, respectively, as well as the recurrence in tumor site in five patients (Table 1). The number of intrathoracic LRR in patients with upper, middle, and lower thoracic EC was 12, 38, and 8, respectively. The recurrence rate of abdominal lymph nodes was 9.8% in the patients with lower thoracic EC, which was higher than upper thoracic EC (0%) and middle thoracic EC (3.9%). There was no significant difference among upper, middle, and lower thoracic portions (χ2 = 4.393, P = 0.111). The SLNM in patients with upper thoracic EC was 12.1%, which was higher than middle thoracic EC (4.6%) and lower thoracic EC (2.4%); there was no significant difference among upper, middle, and lower thoracic portion (χ2 = 4.532, P = 0.104, Table 2).
Table 1

Recurrent sites of 58 cases with intrathoracic LRR

Recurrent site

No.

Rate (%)

Recurrent site

No.

Rate (%)

Sup.LN

6

10.3

Sup. LN+Med.LN+Abd. LN

1

1.7

Med.LN

29

50

Ana.

2

3.4

Abd. LN

4

6.9

Ana.+Med. LN

3

5.2

Sup. LN+Med.LN

3

5.2

Ana. +Abd. LN

1

1.7

Sup..LN+Abd. LN

2

3.4

Tumor site

4

6.9

Med.LN+Abd. LN

2

3.4

Tumor site +Med. LN

1

1.7

Note: Sup: supraclavicular; Med.: mediastinal; Abd.: abdominal; Ana.: anastomotic; LN: lumph node

Table 2

Analysis of recurrence pattern of different lesion locations N (%)

 

Total No.

Upper thoracic portion(33)

Middle thoracic portion (153)

Lower thoracic portion(41)

Χ2

P

Sup.LN

12

4(12.1%)

7(4.6%)

1(2.4%)

4.532

0.104

Med.LN

39

9(27.3%)

26(17.0%)

4(9.8%)

3.954

0.138

Abd. LN

10

0(0%)

6(3.9%)

4(9.8%)

4.393

0.111

Ana.

6

1(3.0%)

3(2.0%)

2(4.9%)

1.092

0.579

Tumor site

5

0(0%)

4(2.6%)

1(2.4%)

0.874

0.646

Note: Sup: supraclavicular; Med.: mediastinal; Abd.: abdominal; Ana.: anastomotic; LN: lumph node. Overlapped recurrence pattern led to double counting of the number of patients with different recurrent sites (that is, the cumulative cases)

Among 27 patients with distant metastases, there were 16 patients with lung metastases (12 patients with simple lung metastasis, and 4 patients recurred accompanied with lung metastasis), 4 patients with liver metastasis (3 patients with simple liver metastasis, and 1 patient recurred accompanied with liver metastasis), 4 patients with bone metastasis (2 patients with simple liver metastasis, and 2 patients recurred accompanied with bone metastasis), 2 patients with brain metastases, and 5 patients with multiple metastases.

Univariate analysis of the prognosis

Univariate analysis of the clinical and pathological data of patients showed that 3- and 5-year OS of patients with upper thoracic EC was significantly lower than that in patients with middle and lower thoracic EC (χ2 = 15.747, P = 0.000). The 3- and 5-year OS of poorly differentiated SCC patients was remarkably lower than that of moderate- and well-differentiated SCC (χ2 = 7.798, P = 0.005). The 3- and 5-year distal metastatic rate of poorly differentiated SCC was notably higher, compared with moderate- and well-differentiated SCC (Χ2 = 19.243, P = 0.000). The 3- and 5-year thoracic LRR rate of patients with upper thoracic EC was significantly higher than that in middle and lower EC patients (χ2 = 5.923, P = 0.047) (Figs. 1, 2, 3, 4, 5, and 6 and Table 3).
Fig. 1
Fig. 1

OS of different lesion locations

Fig. 2
Fig. 2

Thoracic LRR of different lesion locations

Fig. 3
Fig. 3

Distant metastasis rate of different lesion locations

Fig. 4
Fig. 4

Survival rate of different degrees of pathological differentiation

Fig. 5
Fig. 5

Thoracic LRR of different degrees of differentiation

Fig. 6
Fig. 6

Distant metastases of different differentiations

Table 3

Univariate analysis of prognosis of 227 patients with pT3N0 M0 TESCC

Variable

N

OS (%)

Χ2

P

LRR (%)

Χ2

P

DM (%)

Χ2

P

3yr

5yr

3yr

5yr

3yr

5yr

Sex

   

1.819

0.177

  

0.985

0.321

  

2.301

0.129

 Male

160

58.1

45.6

  

22.4

27.1

  

24.1

18.2

  

 Female

67

62.7

53.7

  

32.8

34.7

  

7.4

7.4

  

Age

   

0.513

0.474

  

0.788

0.375

  

0.172

0.678

 ≤62

120

59.2

48.3

  

27.6

32.5

  

14.7

16.0

  

 >62

107

59.8

47.7

  

24.1

26.7

  

9.0

13.7

  

Lymph node by preoperative CT

  

1.326

0.250

  

0.395

0.530

  

0.013

0.908

 No

153

58.2

46.4

  

26.1

29.8

  

10.2

14.7

  

 Yes

44

50.0

40.9

  

31.9

31.9

  

16.2

16.2

  

Lesion location

   

15.747

0.000

  

5.923

0.047

  

0.378

0.828

 Upper

33

30.3

21.2

  

49.2

55.6

  

12.6

22.3

  

 Middle

153

62.7

51.0

  

24.0

27.7

  

12.1

14.2

  

 Lowe

41

70.7

58.5

  

19.2

22.0

  

11.0

14.4

  

Lesion length(cm)

  

0.413

0.520

  

0.098

0.754

  

0.215

0.643

 ≤5

125

55.2

47.2

  

27.0

30.5

  

13.4

14.8

  

 >5

102

64.7

49.0

  

24.9

29.0

  

10.0

14.8

  

Intraoperative adhesion

   

0.487

0.485

  

0.003

0,957

  

0.237

0.627

 No/mild

130

60.0

49.2

  

25.6

29.8

  

12.0

15.8

  

 Moderate/severe

97

58.8

46.4

  

26.6

29.7

  

12.0

13.8

  

Differentiation

  

7.798

0.005

  

1.563

0.211

  

19.243

0.000

 poorly

38

44.7

26.3

  

30.8

40.0

  

31.1

40.9

  

 Moderately to well

189

62.4

52.4

  

25.0

27.9

  

8.0

9.7

  

No. of lymph nodes removed(No.)

 

2.422

0.120

  

0.001

0.978

  

0.007

0.935

 ≤10

133

57.1

43.6

  

26.9

30.3

  

12.1

14.9

  

 >10

94

62.8

54.3

  

24.9

29.1

  

11.7

14.9

  

Multivariate analysis of the prognosis of patients

The influencing factors for prognosis of patients were put into the Cox model for multivariate analysis. The results revealed that the degree of differentiation and lesion location were independent prognostic factors for OS of patients (P = 0.014, 0.010). Lesion location was the independent influencing factor for thoracic LRR (P = 0.46). The degree of differentiation was the independent influencing factor for distant metastasis (P = 0.000) (Table 4).
Table 4

Multivariate analysis of prognosis in 227 patients with pT3N0M0 TESCC

Variable

B

SE

Wald

P

OB

95%CI

Lower

Upper

OS

 Differentiation

0.429

0.174

6.082

0.014

0.651

0.463

0.916

 Lesion location

0.567

0.221

6.594

0.010

0.567

0.368

0.874

LRR

 Lesion location

0.498

0.247

3.997

0.046

0.598

0.362

0.990

DM

 Differentiation

1.727

0.421

16.825

0.000

0.178

0.078

0.406

Discussion

In the present study, patients with pT3N0M0 TESCC undergoing surgery alone were followed up for 5 years. Among them, 58 patients experienced intrathoracic LRR, with a recurrence rate of 25.6%. Most patients recurred in 1 to 2 years after surgery, with a median recurrence time of 16.4 months. The median survival time of patients after recurrence was 5.6 months, ranging from 0.6 to 46.7 months. The most common area for recurrence is the thorax, specifically the mediastinal lymph nodes. The results showed that simple mediastinal lymphatic recurrence rate was as high as 50.0% (29/58), and the recurrence rate of other areas was less than 10%. These findings suggested that major postoperative failure for pT3N0M0 TESCC patients was attributed to mediastinal lymphatic recurrence. This was consistent with the results of previous studies. Yang et al. [7] compared surgery alone and PORT in 916 patients with pT2-3N0M0 TESCC. Wang et al. [8] analyzed failure pattern of 208 patients with pT3N0M0 TESCC, and the results indicated a LRR rate of 25.0% and the mediastinal lymph nodes being the most common recurrent site, with a median recurrence time of 15.5 months. Zhang et al. [9] reported that a total of 467 patients met the inclusion criteria (including 228 pT3N0M0 patients) according to the analysis of survival factors affecting stage II EC patients. Therefore, we propose that in terms of postoperative adjuvant therapy for patients with pT3N0M0 TESCC, the mediastinal lymph node is the primary focus.

Appropriate prophylactic PORT in theory can reduce the recurrence rate of mediastinal lymph nodes in the thoracic cavity, thereby improving OS of patients. However, in the era of two-dimensional radiotherapy (2D-RT), PORT for the lymph node-negative patients with EC mainly led to unsatisfactory improvement of their survival. For example, Xiao et al. [4] indicated that compared with those undergoing surgery alone, 3-year OS of patients with pT3N0M0 EC receiving PORT was increased by 8%; there was no difference in 5-year OS. Chen et al. [1] found patients with negative lymph nodes confirmed by postoperative pathology did not benefit from PORT, and advances in 3D-CRT and intensity-modulated RT contributed to the rapid development of adjuvant PORT for EC.

In recent years, the application of 3D-CRT to adjuvant therapy for pN0 EC has been reported, which was of great significance to clinicians. Yang et al. [10] demonstrated that the 5-year OS and progression-free survival rates were 74 and 71%, assuming that 3D-CRT was safe and effective for postoperative patients with pT2-3N0M0 EC, and the recurrence rate and survival rates were higher than previously reported in the literature. We deem that 3D-CRT is advantageous over 2D-RT in the target dose distribution and normal tissue volume. However, the actual survival benefit should be further validated with more cases accumulated.

There is no international consensus as to the role of adjuvant PORT for EC, which may be related to inclusion criteria, surgical methods, irradiation mode, extent of exposure, and radiotherapy technologies used in different research centers. Currently, stratification analysis is recommended in most clinical studies. Therefore, postoperative adjuvant therapy may produce different results in patients with pT3N0M0 TESCC, thus stratification analysis was performed on all patients enrolled. We found that the lesion location was the independent influencing factor for OS and recurrence of pT3N0M0 TESCC patients. OS was significantly lower in patients with upper thoracic EC than those with middle and lower thoracic EC, accompanied with notably higher recurrence, which is in accordance with most of the previous reports [11]. This may be related to the different anatomical structures of different lesions. The higher location of the upper thoracic lesions leads to incomplete removal of lymph nodes in the corresponding areas [12]. This may also be associated with left thoracic RO and two-field (thorax+abdomen) lymphadenectomy. Limited surgical field of vision led to insufficient removal of mediastinal lymph nodes in drainage area, giving rise to high recurrence rate in this area. However, other studies reported lesions were not related to postoperative recurrence of EC. For example, Liu et al. [13] reported different lesions were not significantly associated with lymph node recurrence. Based on our findings, we recommend PORT to patients with pT3N0M0 thoracic EC after thoracic and abdominal lymph node dissection.

In this study, the removed lymph node median number in EC patients was 10, which was less than Western countries [1416]. Chen et al. [17] suggested that the removed lymph node number < 6 might lead metastatic lymph node omission, thus affecting the accuracy of the N grade. According to UICC, the number of surgically removed lymph nodes is reasonably suggested to be no less than six. We believe that the more thorough lymph nodes dissected intraoperatively, the less possibility of lymph node metastasis, thereby reducing the LRR rate of patients and improving the survival rate of patients. Nonetheless, further study is needed to explore whether the benefit brought by lymph node dissection is offset by its negative effect on the patient’s immunity. The prognostic factors that affect the distant metastasis in this group were shown to be closely associated with the degree of disease differentiation. Additionally, consistent with the conclusions of most studies [5, 13, 18], the distant metastasis rate of poorly differentiated EC was significantly higher than that of moderately and well-differentiated EC. Advances in comprehensive treatments and their increased application in clinical treatment of EC have gradually established the standard treatment of postoperative EC using PORT combined with POCT. Postoperative radiochemotherapy (PORCT) can improve the long-term survival of EC patients [19], but further studies are required to confirm whether PORCT can effectively reduce distant metastasis rate of the pT3N0M0 TESCC, thereby improving the survival rate.

Conclusion

In summary, the results of the present study reveal that intrathoracic LRR of pT3N0M0 TESCC after conventional two-field (thoracic and abdominal) lymphadenectomy contributes to treatment failure, and most of the recurrence occurs within 2 years after surgery. The lesion is the main influencing factor for prognosis and recurrence, and the recurrence rate of patients with upper thoracic EC was significantly higher than that in the middle and lower thoracic EC. Therefore, PORT is strongly recommended for pT3N0M0 TESCC patients to reduce postoperative recurrence rate of mediastinal lymph nodes in thoracic cavity. For patients with poorly differentiated EC, selection of CT needs further confirmation.

Declarations

Acknowledgements

Not applicable

Funding

None

Availability of data and materials

Not applicable

Authors’ contributions

SZ put forward the concept of the study, designed the study, prepared the manuscript, and contributed to the statistical analysis. HG and JX contributed to the data acquisition. YL contributed to the quality control of data and algorithms. SL analyzed the data and interpretation. WS edited the manuscript. SZ put forward the concept of the study, contributed to the data analysis and interpretation, and reviewed the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The study was approved by the ethics committee of the Fourth Hospital of Hebei Medical University.

Consent for publication

The study was undertaken with the patient’s consent.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, No. 12 Jiankan Road, Chang’an District, Shijiazhaung, 050011, China
(2)
Department of Radiation, The First Hospital of Shijiazhaung, Shijiazhaung, 050011, China

References

  1. Chen J, et al. Postoperative radiotherapy improved survival of poor prognostic squamous cell carcinoma esophagus. Ann Thorac Surg. 2010;90(2):435–42.View ArticlePubMedGoogle Scholar
  2. Martin JT, et al. The role of radiation therapy in resected T2 N0 esophageal cancer: a population-based analysis. Ann Thorac Surg. 2013;95(2):453–8.View ArticlePubMedGoogle Scholar
  3. Smit JK, et al. Prognostic factors and patterns of recurrence in esophageal cancer assert arguments for extended two-field transthoracic esophagectomy. Am J Surg. 2010;200(4):446–53.View ArticlePubMedGoogle Scholar
  4. Xiao ZF, et al. Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients. Ann Thorac Surg. 2003;75(2):331–6.View ArticlePubMedGoogle Scholar
  5. Xu Y, et al. Factors influencing the risk of recurrence in patients with esophageal carcinoma treated with surgery: a single institution analysis consisting of 1002 cases. Oncol Lett. 2013;5(1):185–90.PubMedGoogle Scholar
  6. Huang YC, et al. The efficacy of postoperative adjuvant chemotherapy for patients with pT3N0M0 upper tract urothelial carcinoma. J Urol. 2015;194(2):323.View ArticlePubMedGoogle Scholar
  7. Yang J, et al. Postoperative adjuvant three-dimensional conformal radiotherapy improves long-term survival in patients with pathological T2-3N0M0 esophageal cancer. Chi J Radiat Oncol. 2015;24(2):101–5.Google Scholar
  8. Wang YX, et al. Patterns of recurrence in patients with stage pT3N0M0 thoracic esophageal squamous cell carcinoma after two-field esophagectomy. Zhonghua Zhong Liu Za Zhi. 2015;1(5):48–54.Google Scholar
  9. Zhang DK, Su XD, Lin P. Survival analysis of patients with stage II squamous cell carcinoma of the thoracic esophagus after esophagectomy. Ai Zheng. 2008;27(2):113–8.PubMedGoogle Scholar
  10. Yang J, et al. Prospective phase II study of three-dimensional radiotherapy after radical surgery for pT2-3N0M0 esophageal cancer. Chin J Radiat Oncol. 2015;24(1):29–32.Google Scholar
  11. Guo XF, et al. Clinical study on postoperative recurrence in patients with pN0 esophageal squamous cell carcinoma. J Cardiothorac Surg. 2014;9:150.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Gao XS, et al. Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinoma. Int J Radiat Oncol Biol Phys. 2007;67(2):389–96.View ArticlePubMedGoogle Scholar
  13. Liu Q, et al. Patterns of failure after radical surgery among patients with thoracic esophageal squamous cell carcinoma: implications for the clinical target volume design of postoperative radiotherapy. PLoS One. 2014;9(5):e97225.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Greenstein AJ, et al. Effect of the number of lymph nodes sampled on postoperative survival of lymph node-negative esophageal cancer. Cancer. 2008;112(6):1239–46.View ArticlePubMedGoogle Scholar
  15. Rizk N, et al. The prognostic importance of the number of involved lymph nodes in esophageal cancer: implications for revisions of the American Joint Committee on Cancer staging system. J Thorac Cardiovasc Surg. 2006;132(6):1374–81.View ArticlePubMedGoogle Scholar
  16. Bollschweiler E, et al. Staging of esophageal carcinoma: length of tumor and number of involved regional lymph nodes. Are these independent prognostic factors? J Surg Oncol. 2006;94(5):355–63.View ArticlePubMedGoogle Scholar
  17. Chen LQ, et al. Influence of number of removed lymph nodes on the TNM staging and survival in advanced esophageal carcinoma. Chin J Oncol. 2007;29(8):604.Google Scholar
  18. Chen XL, et al. Patterns of lymph node recurrence after radical surgery impacting on survival of patients with pT1-3N0M0 thoracic esophageal squamous cell carcinoma. J Korean Med Sci. 2014;29(2):217–23.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Hsu PK, et al. Survival benefits of postoperative chemoradiation for lymph node-positive esophageal squamous cell carcinoma. Ann Thorac Surg. 2014;97(5):1734–41.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement